New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons

Regulations by 2FIRSTS.ai
Nov.29.2023
New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons
New Zealand's landmark smoking ban law, aimed at achieving a "smoke-free generation," has been repealed by the new government.

According to a report by Hipertextual, former New Zealand Prime Minister Jacinda Ardern announced a groundbreaking tobacco control law in 2021, with the aim of achieving a "smoke-free generation" and saving thousands of lives. The law received widespread support from health legislators around the world, with several countries announcing plans to follow suit. However, the new government in New Zealand repealed the law before it could be enacted, and openly admitted that the decision was driven by economic interests.

 

New Zealand's smoking ban bill aims to achieve its goals by gradually increasing the legal smoking age. Currently, in New Zealand and many other countries, the legal age for smoking is 18. The initial plan is to raise the age to 19 by 2026, followed by an annual increase of one year thereafter. Eventually, teenagers will no longer be permitted to smoke. Despite potentially appearing strict, this regulation is expected to save millions of lives and cost millions of dollars in healthcare expenses.

 

However, in the election, the newly elected government in New Zealand has promised to implement a historic tax reduction, which requires a complete overhaul. Given that the tobacco industry brings in a significant amount of revenue for the government, the newly elected right-wing coalition government wasted no time in making this decision.

 

Newly-appointed Minister of Finance, Nicola Willis, has announced the repeal of the smoking ban bill. This decision, driven by economic factors, did not originate from the Health Ministry. The tobacco industry contributes approximately $2 billion in tax revenue to the New Zealand government annually, making it an effective avenue for offsetting tax deductions.

 

A recent study suggests that Ardern's smoking ban bill could save $1.3 billion in healthcare costs over the next 20 years. However, this does not offset the profits from tobacco sales, thus making it an insufficiently compelling reason for the new government.

 

Furthermore, the World Health Organization (WHO) stated in its tobacco report that approximately 8 million people die each year globally due to smoking-related causes. Out of this number, 7 million people die directly from smoking, while the remaining 1 million are second-hand smoke inhalers. These individuals do not willingly smoke, yet they tragically lose their lives due to exposure to cigarette smoke.

 

Achieving a smoke-free generation is just one of the many proposed measures by the World Health Organization to prevent health issues caused by tobacco. Other measures include conducting health promotion campaigns to assist people in quitting smoking, issuing graphic health warnings, increasing taxes on tobacco companies, and regulating nicotine-containing products such as e-cigarettes.

 

At the beginning of this year, the Director-General of the organization, Tedros Adhanom Ghebreyesus, stated that only four countries in the world have implemented a comprehensive set of measures following most of the organization's recommendations. These countries include Brazil, Mauritius, Turkey, and the Netherlands. Among the member states of the European Union, only the Netherlands has achieved this feat. However, data shows that approximately 18.4% of the population aged 15 and above reported being daily smokers in 2019. The highest smoking rate was recorded in Bulgaria at 28.7%, while Sweden had the lowest at 6.4%.

 

Fortunately, several countries, such as Portugal, have started implementing the smoking ban law repealed by New Zealand and have also set goals to achieve a smoke-free generation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28